Latin America Peptide Therapeutics Market

Latin America Peptide Therapeutics Market Size

The Latin America peptide therapeutics market was valued at USD 3.81 billion in 2024 and is forecasted to reach USD 9.90 billion by 2033, expanding at a CAGR of 11.19%.

MARKET DRIVERS

Rising Disease Burden and R&D Investments Fuel Peptide Therapeutics Growth

The key factors driving the market's growth include the increased incidence of various disorders such as cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others, as well as the availability and development of advanced drugs for treatment. In addition, the market's growth is also associated with increased investments in R&D for drug discovery and the presence of a strong product portfolio in the market. In addition, the increase in clinical trials in the market also boosts the Latin American peptide therapeutics market during the forecast period.

Since 2019, more than $ 3 billion has been invested in companies involved in developing various types of peptide drugs. In addition, the market is experiencing significant associative activity; recently, players in this industry signed several licensing agreements focused on developing and commercializing drugs. Due to their proven pharmacological value, the demand for peptide drugs is undoubtedly expected to increase in the coming years.

The application of peptide therapeutics in cancer treatment has opened up a promising avenue for the future growth of the Latin American peptide therapeutics market. Advances in technology have been beneficial in reducing the overall costs involved in the production of peptide therapies. This has prompted manufacturers and suppliers to pioneer new ways of making peptide therapies and tackling long and complex peptide chains. The radical shift towards hybrid technologies to reduce the strain on resources is likely to boost the short term of the Latin American peptide therapeutics market.

MARKET RESTRAINTS

Low Stability and Poor Oral Availability Limit Peptide Therapeutics Growth

The Latin American peptide therapeutics market is expected to be hampered by the low chemical and physical stability of natural peptides and their limited half-life in circulating plasma. Additionally, since the peptide drugs are administered by injection, low oral availability and poor penetration of intestinal mucosa are expected to limit market growth in the near future.

REPORT COVERAGE

COUNTRY LEVEL ANALYSIS

Geographically, the Brazilian peptide therapeutics market is expected to dominate the Latin American market throughout the forecast period.

The market's growth is driven by factors such as increasing awareness levels related to peptide therapies, the growing need for diagnostics for cancer and other diseases, and the growing biotechnology industry.

Contract Manufacturing Organizations (CMOs) that provide end-to-end services to biotech and pharmaceutical companies are getting a lot of attention because they provide a better manufacturing and fulfillment experience. Peptide therapy market players are placing more emphasis on outsourcing drug manufacturing to CMOs to reduce operating expenses. The manufacturing of peptide therapies offers limited space for players to develop distinctive strategies to secure a competitive advantage. In addition, rising contract manufacturing allows market players to add technical resources to their existing business models.

The high prevalence of cancer and the increasing incidence rate of new cancer cases are expected to drive the market in Mexico during the forecast period. On the other hand, other peptide therapeutic drugs recently introduced or in advanced stages of clinical trials are expected to retain a significant share of the global peptide therapy market at the end of the forecast period. Additionally, the peptide therapeutics market in Argentina is expected to grow significantly during the forecast period. The rise of biotechnology companies and increasing healthcare spending by government authorities, the increasing prevalence of cancer and nervous system disorders are some of the factors that are expected to drive demand for Latin American peptide therapeutics in the future.

KEY MARKET PLAYERS

Some of the key players operating in the Latin American peptide therapeutics market profiled in this report are Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals.

MARKET SEGMENTATION

This research report on the Latin American peptide therapeutics market has been segmented and sub-segmented into the following categories.

By Type

• Generic

• Innovative

By Application

• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others

By Type of Manufacturers

• In-house
• Outsourced

By Route of Administration

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Country

• Brazil
• Mexico
• Argentina
• Chile
• Rest of Latin America